Physician profile
Ryan D Richards
NPI 1558716795
$1,555.78
in general payments reported to CMS, 2019-2025
13 companies · $621 in 2025
The $621 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $45.17 · 2023: $289 · 2024: $600 · 2025: $621.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,510.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $245.81 | 2023-2025 | Qelbree, Qelbree |
| Lundbeck LLC | $211.98 | 2023-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $166.17 | 2022-2024 | Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $163.74 | 2023-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $156.44 | 2023-2025 | Auvelity |
| Corium, LLC | $132.30 | 2023-2025 | Azstarys, Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $113.01 | 2024-2025 | Caplyta |
| Ironshore Pharmaceuticals INC. | $107.52 | 2022-2024 | |
| Abbvie INC. | $100.44 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $75.61 | 2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $49.60 | 2025 | Jornay Pm |
| Neurocrine Biosciences, INC. | $19.12 | 2023 | |
| Alkermes, INC. | $14.04 | 2024 | Aristada, Lybalvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Richards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.